(2026). Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: A pooled analysis. The Oncologist.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Prevalence of Adverse Events Following T-cell Redirecting Therapies in Patients with Metastatic Castration-resistant Prostate Cancer: A Pooled Analysis."
The Oncologist 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Prevalence of Adverse Events Following T-cell Redirecting Therapies in Patients with Metastatic Castration-resistant Prostate Cancer: A Pooled Analysis."
The Oncologist, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.